Persistent Strengthens Life Sciences AI Through Databricks
SANTA CLARA, Calif. and PUNE, India , May 7, 2026 Persistent Systems announced it has achieved the Databricks Brickbuilder...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SANTA CLARA, Calif. and PUNE, India , May 7, 2026 Persistent Systems announced it has achieved the Databricks Brickbuilder...
TORONTO, Ontario — March 11, 2026 Younet.ai, a Toronto-based artificial intelligence technology company specializing in enterprise-grade private large language...
